DiaMedica Therapeutics Inc. Common Stock DMAC
i
Market datapartial · fetched 2026-11-11T13:48:54.146Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:00.106179789Z
FundamentalsAlpha Vantage · unavailable
DiaMedica Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.81 | 651.4% | 53.4% | |||
| 25Δ | 7.85 | 591.6% | 42.9% | |||
| 30Δ | 12.24 | 204.4% | 31.7% | 8.55 | 520.1% | 36.1% |
| 35Δ | 11.66 | 190.4% | 26.4% | 9.25 | 448.5% | 29.3% |
| 40Δ | 11.08 | 176.3% | 21.2% | 9.95 | 376.9% | 22.5% |
| 45Δ | 10.50 | 162.2% | 15.9% | 10.35 | 347.9% | 19.5% |
| 50Δ | 9.95 | 150.6% | 11.2% | 10.74 | 322.4% | 16.8% |
| 55Δ | 9.60 | 155.4% | 9.9% | 11.12 | 296.9% | 14.2% |
| 60Δ | 9.25 | 160.2% | 8.7% | 11.50 | 271.4% | 11.5% |
| 65Δ | 8.89 | 165.0% | 7.5% | 11.88 | 245.9% | 8.8% |
| 70Δ | 8.54 | 169.8% | 6.3% | 12.26 | 220.5% | 6.1% |
| 75Δ | 8.18 | 174.5% | 5.1% | 12.86 | 206.1% | 4.1% |
| 80Δ | 7.83 | 179.3% | 3.9% | 13.79 | 210.0% | 3.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.81
- IV
- 651.4%
- B/E move
- 53.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.85
- IV
- 591.6%
- B/E move
- 42.9%
30Δ
- Pseudo strike
- 12.24
- IV
- 204.4%
- B/E move
- 31.7%
- Pseudo strike
- 8.55
- IV
- 520.1%
- B/E move
- 36.1%
35Δ
- Pseudo strike
- 11.66
- IV
- 190.4%
- B/E move
- 26.4%
- Pseudo strike
- 9.25
- IV
- 448.5%
- B/E move
- 29.3%
40Δ
- Pseudo strike
- 11.08
- IV
- 176.3%
- B/E move
- 21.2%
- Pseudo strike
- 9.95
- IV
- 376.9%
- B/E move
- 22.5%
45Δ
- Pseudo strike
- 10.50
- IV
- 162.2%
- B/E move
- 15.9%
- Pseudo strike
- 10.35
- IV
- 347.9%
- B/E move
- 19.5%
50Δ
- Pseudo strike
- 9.95
- IV
- 150.6%
- B/E move
- 11.2%
- Pseudo strike
- 10.74
- IV
- 322.4%
- B/E move
- 16.8%
55Δ
- Pseudo strike
- 9.60
- IV
- 155.4%
- B/E move
- 9.9%
- Pseudo strike
- 11.12
- IV
- 296.9%
- B/E move
- 14.2%
60Δ
- Pseudo strike
- 9.25
- IV
- 160.2%
- B/E move
- 8.7%
- Pseudo strike
- 11.50
- IV
- 271.4%
- B/E move
- 11.5%
65Δ
- Pseudo strike
- 8.89
- IV
- 165.0%
- B/E move
- 7.5%
- Pseudo strike
- 11.88
- IV
- 245.9%
- B/E move
- 8.8%
70Δ
- Pseudo strike
- 8.54
- IV
- 169.8%
- B/E move
- 6.3%
- Pseudo strike
- 12.26
- IV
- 220.5%
- B/E move
- 6.1%
75Δ
- Pseudo strike
- 8.18
- IV
- 174.5%
- B/E move
- 5.1%
- Pseudo strike
- 12.86
- IV
- 206.1%
- B/E move
- 4.1%
80Δ
- Pseudo strike
- 7.83
- IV
- 179.3%
- B/E move
- 3.9%
- Pseudo strike
- 13.79
- IV
- 210.0%
- B/E move
- 3.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 141.70% | |
| 141.53% | |
| 125.99% | |
| 136.99% | |
| 135.30% | |
| 104.80% | |
| 105.14% | |
| 148.49% |
Biotechnology
DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Description unavailable
More →